The Comparison of Tibolone and Hormone Replacement Therapy on Bone Densitometry and Bone Turnover in Postmenopausal Women
Scimetr: April 30, 2014, 2 (2); e87407
April 23, 2014
Article Type: Research Article
December 28, 2013
February 22, 2014
Z , Ziaei
S . The Comparison of Tibolone and Hormone Replacement Therapy on Bone Densitometry and Bone Turnover in Postmenopausal Women,
Background: Osteoporosis is a prevalent disease related to menopause, and causes an increasing health problem.
Objectives: Our aim was to compare the effects of conventional estrogen replacement therapy and tibolone on the bone mineral density (BMD) and bone turn over in postmenopausal women.
Patients and Methods: A total of 150 healthy non-surgical postmenopausal women in Iran were enrolled in a randomized controlled clinical trial. Fifty women received 2.5 mg tibolone plus one calcium + D tablet (500 mg Ca and 200 IU vitamin D) daily; 50 women received 0.625 mg conjugated equine estrogen and 2.5 mg medroxy progesterone acetate (CEE/MPA) plus one calcium + D tablet daily; 50 women received only one calcium + D tablet and served as a control group. Bone densitometry (DAX) of the lumbar spine and the proximal femoral neck and also bone turnover markers (serum alkaline phosphates (ALP) and urine Ca/Cr ratio) measured at baseline and after the nine months of entering into the study.
Results: After the treatments, ALP reduced significantly in the CEE/MPA and tibolone groups (P = 0.02, P = 0.002), but increased in the control group (P = 0.03) in comparison with the baseline. After the treatments with respect to femoral BMD, significantly increase occurred only in the tibolone group in comparison with the baseline (0.95 ± 0.13, 0.97 ± 0.12, P = 0.004).
Conclusions: Tibolone may be considered as an alternative for preventing of osteoporosis in postmenopausal women.